Dave Ricks

Bill Browder, founder and CEO of Hermitage Capital Management explains how he became one of Vladimir Putin's most wanted critics - and why his fight put his life at risk. He discusses his rise as the largest foreign investor in Russia during the 1990s privatization boom and how e ...  Show more

Billionaire investor Ray Dalio joins David Rubenstein for a wide-ranging conversation on the risks facing the US economy; from soaring debt and currency devaluation to tariffs and inflation - and why gold remains "money" in times of stress. He's on this week's episode of The Davi ...  Show more

Benjamin Y. Fong is author of the new book Quick Fixes: Drugs in America from Prohibition to the 21st Century Binge, which was just released in July, 2023 by Verso Books. Ben is an honors faculty fellow and associate director of the Center for Work & Democracy at Arizona State Un ...  Show more

Carl Quintanilla and Jim Cramer led off the show by delving into the broadening market rally, as the S&P 500 and Nasdaq aim for a ninth consecutive day of gains. David Faber called into the show with reporting on Edgar Bronfman's bid to acquire Paramount Global. Eli Lilly CEO ...

Karen Andersen, biotechnology strategist for Morningstar Research Services, discusses what GLP-1 drugs’ demand means for the biopharma industry’s five-year outlook. And whether the weight-loss drugs pose a threat to snack food stocks.

Why GLP-1 Drugs Are in Demand 

We've curated a special 10-minute version of the podcast for those in a hurry.   Here you can listen to the full episode:  https://podcasts.apple.com/no/podcast/eli-lilly-ceo-the-weight-loss-drug-revolution-ai-in/id1614211565?i=1000693848152&l=nb Nicolai Tangen meets with David Ri ...  Show more